Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures...
Pfizer's $70 billion U.S. investment deal exempts it from tariffs, boosting drugmaker stocks.
Pfizer's $70 billion U.S. investment deal exempts it from tariffs, boosting drugmaker stocks.
Trump's deal with Pfizer exempts it from tariffs, boosting drugmaker stocks.
FDA's PreCheck program aims to boost U.S. drug manufacturing by reducing regulatory hurdles.